文献速递间质性肺疾病

lebrikizumab治疗特发性肺纤维化的2期试验

Phase 2 trial to assess lebrikizumab in patients with idiopathic pulmonary fibrosis.
PubMed 文献 · Eur Respir J · 2021-02-04

这项2期随机双盲安慰剂对照试验评估了IL-13单抗lebrikizumab单用或联合吡非尼酮治疗IPF的疗效与安全性。主要终点(52周FVC%预计值年下降率)在初治队列(-5.2% vs -6.2%,p=0.456)和吡非尼酮背景队列(-5.5% vs -6.0%,p=0.557)均未达到。lebrikizumab耐受良好,但未减少肺功能下降。

要点

  • lebrikizumab单用或联合吡非尼酮均未显著减少52周FVC%预计值下降。
  • 初治队列FVC年下降率lebrikizumab组-5.2% vs 安慰剂组-6.2%(p=0.456)。
  • 吡非尼酮背景队列FVC年下降率lebrikizumab组-5.5% vs 安慰剂组-6.0%(p=0.557)。

核心结论

  • lebrikizumab单用或联合吡非尼酮未减少52周FVC%预计值下降,尽管有药效动力学活性证据。
  • lebrikizumab耐受良好,安全性特征与既往单药研究一致。
  • 阻断IL-13可能不足以在IPF患者中实现肺功能获益。

研究设计与样本

  • 2期随机双盲安慰剂对照试验,评估lebrikizumab(IL-13单抗)单用或联合吡非尼酮治疗IPF。
  • 纳入≥40岁、FVC 40%-100%预计值、DLCO 25%-90%预计值的IPF患者。
  • 队列A为初治患者,随机154例至lebrikizumab 250 mg(n=78)或安慰剂(n=76)皮下每4周一次。
  • 队列B为接受吡非尼酮2403 mg·day-1治疗者,随机351例至lebrikizumab(n=174)或安慰剂(n=177)。

主要发现

  • 主要终点(52周FVC%预计值年下降率)在队列A未达到:lebrikizumab vs 安慰剂 -5.2% vs -6.2%,p=0.456。
  • 主要终点在队列B未达到:lebrikizumab vs 安慰剂 -5.5% vs -6.0%,p=0.557。
  • 队列B中联合治疗组死亡风险有非统计学显著的不均衡倾向(HR 0.42,95%CI 0.17-1.04)。
  • 药效动力学生物标志物显示lebrikizumab具有活性。

临床怎么用

  • 不推荐在IPF患者中使用lebrikizumab以期延缓肺功能下降。
  • 该结果提示单纯阻断IL-13可能不足以改善IPF患者肺功能。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

This phase 2, randomised, double-blind, placebo-controlled trial evaluated the efficacy and safety of lebrikizumab, an interleukin (IL)-13 monoclonal antibody, alone or with background pirfenidone therapy, in patients with idiopathic pulmonary fibrosis (IPF).Patients with IPF aged ≥40 years with forced vital capacity (FVC) of 40%-100% predicted and diffusing capacity for carbon monoxide of 25%-90% predicted and who were treatment-naïve (cohort A) or receiving pirfenidone (2403 mg·day-1; cohort B) were randomised 1:1 to receive lebrikizumab 250 mg or placebo subcutaneously every 4 weeks. The primary endpoint was annualised rate of FVC % predicted decline over 52 weeks.In cohort A, 154 patients were randomised to receive lebrikizumab (n=78) or placebo (n=76). In cohort B, 351 patients receiving pirfenidone were randomised to receive lebrikizumab (n=174) or placebo (n=177). Baseline demographics were balanced across treatment arms in both cohorts. The primary endpoint (annualised rate of FVC % predicted decline) was not met in cohort A (lebrikizumab versus placebo, -5.2% versus -6.2%; p=0.456) or cohort B (lebrikizumab versus placebo, -5.5% versus -6.0%; p=0.557). In cohort B, a non-statistically significant imbalance in mortality favouring combination therapy was observed (hazard ratio 0.42 (95% CI 0.17-1.04)). Pharmacodynamic biomarkers indicated lebrikizumab activity. The safety profile was consistent with that in previous studies of lebrikizumab and pirfenidone as monotherapies.Lebrikizumab alone or with pirfenidone was not associated with reduced FVC % predicted decline over 52 weeks despite evidence of pharmacodynamic activity. Lebrikizumab was well tolerated with a favourable safety profile. These findings suggest that blocking IL-13 may not be sufficient to achieve a lung function benefit in patients with IPF.

来源:Eur Respir J,查看原文。版权归原作者所有。

引用

  1. Maher TM, Costabel U, Glassberg MK, et al. Phase 2 trial to assess lebrikizumab in patients with idiopathic pulmonary fibrosis. Eur Respir J. 2021. PMID: 33008934. doi:10.1183/13993003.02442-2019

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。